Bavarian Nordic Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Bavarian Nordic is forecast to grow earnings and revenue by 9.2% and 1.6% per annum respectively. EPS is expected to grow by 9% per annum. Return on equity is forecast to be 14.8% in 3 years.

Anahtar bilgiler

9.2%

Kazanç büyüme oranı

9.0%

EPS büyüme oranı

Biotechs kazanç büyümesi	37.3%
Gelir büyüme oranı	1.6%
Gelecekteki özkaynak getirisi	14.8%
Analist kapsamı	Low
Son güncelleme	01 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

LSE:0DPB - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (DKK Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	6,673	1,632	3,769	2,620	3
12/31/2025	6,993	1,964	3,987	3,159	4
12/31/2024	5,755	889	495	807	2
6/30/2024	6,083	707	882	1,958	N/A
3/31/2024	6,642	984	1,028	1,769	N/A
12/31/2023	7,062	1,475	142	1,119	N/A
9/30/2023	5,906	723	-793	751	N/A
6/30/2023	5,533	1,076	-979	568	N/A
3/31/2023	4,083	301	-1,344	-18	N/A
12/31/2022	3,151	-347	-1,162	220	N/A
9/30/2022	2,404	-599	-1,345	-109	N/A
6/30/2022	1,849	-693	-1,342	-101	N/A
3/31/2022	1,683	-606	-1,477	-215	N/A
12/31/2021	1,898	-465	-1,417	-358	N/A
9/30/2021	1,583	-737	-1,541	-663	N/A
6/30/2021	1,693	-629	-1,279	-478	N/A
3/31/2021	2,022	-368	-727	20	N/A
12/31/2020	1,852	278	-135	572	N/A
9/30/2020	1,914	606	-1,613	981	N/A
6/30/2020	1,499	481	-1,970	623	N/A
3/31/2020	901	267	-2,427	227	N/A
12/31/2019	662	-347	-2,947	-276	N/A
9/30/2019	554	-402	-645	-262	N/A
6/30/2019	631	-271	-529	-204	N/A
3/31/2019	616	-279	-408	-152	N/A
12/31/2018	501	-362	-500	-289	N/A
9/30/2018	360	-445	-647	-467	N/A
6/30/2018	873	-151	-706	-564	N/A
3/31/2018	1,184	5	N/A	-158	N/A
12/31/2017	1,370	181	N/A	216	N/A
9/30/2017	1,745	453	N/A	1,030	N/A
6/30/2017	1,463	225	N/A	880	N/A
3/31/2017	1,182	153	N/A	501	N/A
12/31/2016	1,007	31	N/A	268	N/A
9/30/2016	909	-54	N/A	-539	N/A
6/30/2016	536	-202	N/A	-345	N/A
3/31/2016	808	-115	N/A	-561	N/A
12/31/2015	1,021	59	N/A	105	N/A
9/30/2015	1,244	155	N/A	818	N/A
6/30/2015	1,390	186	N/A	815	N/A
3/31/2015	1,166	70	N/A	1,018	N/A
12/31/2014	1,217	26	N/A	339	N/A
9/30/2014	1,013	-99	N/A	-63	N/A
6/30/2014	1,107	-61	N/A	-105	N/A
3/31/2014	1,293	-12	N/A	180	N/A
12/31/2013	1,213	-47	N/A	147	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 0DPB's forecast earnings growth (9.2% per year) is above the savings rate (1.9%).

Kazançlar ve Piyasa: 0DPB's earnings (9.2% per year) are forecast to grow slower than the UK market (14.4% per year).

Yüksek Büyüme Kazançları: 0DPB's earnings are forecast to grow, but not significantly.

Gelir ve Pazar: 0DPB's revenue (1.6% per year) is forecast to grow slower than the UK market (3.6% per year).

Yüksek Büyüme Geliri: 0DPB's revenue (1.6% per year) is forecast to grow slower than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 0DPB's Return on Equity is forecast to be low in 3 years time (14.8%).

Bavarian Nordic Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Recent updates

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

CEO & President recently sold kr.24m worth of stock

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Second quarter 2024 earnings released

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Investor sentiment improves as stock rises 17%

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Investor sentiment improves as stock rises 16%

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 26%

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Now 21% undervalued

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold kr.508k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr.0.20 (vs kr.1.30 loss in 3Q 2021)

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Second quarter 2022 earnings released: kr.3.40 loss per share (vs kr.2.40 loss in 2Q 2021)

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

First quarter 2022 earnings released

Now 41% undervalued